Talking about this from Sat. PR: "1) Statistica

Talking about this from Sat. PR:

"1) Statistically significant results (p-value = 0.0319) reported for the primary endpoint (all-cause mortality at Day 28) in participants receiving leronlimab + “commonly used COVID-19 treatments” compared to participants who received “commonly used COVID-19 treatments” alone in the placebo group in the overall modified intent-to-treat (“mITT”) population."

Nader in Been interview said there were 309 subjects in this group, unless I misunderstood.

however, it's a subgroup, mITT (apparently all who got the "commonly used COVID-19 treatments"

Been interview poor transcript:

"now here s our primary endpoint that everybody wants to know there are three things that we have to talk about modified intended to treat why modified why not just intended to treat because intended to treat was 394 modified intended to treat was 384 those 10 patients signed consent but they did not get enrolled so you can t you don t have neuron demand or placebo so they re not evaluable these are in the sap statistical analysis plan before beyond blind then so now we got 384 what happened over there the 384 309 of them took this the commonly used corvette 19 treatment that we listed in the protocol those patients who took those p value was 0 0319 primary endpoints of 28 days mortality was hit"

much easier to search than going through the video:

https://www.youtube-transcript.com/

https://www.youtube.com/watch?v=Xduqr2uDkSw